| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 666 | 2010 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 530 | 2021 |
| Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind … F Raffi, H Jaeger, E Quiros-Roldan, H Albrecht, E Belonosova, JM Gatell, ... The Lancet infectious diseases 13 (11), 927-935, 2013 | 522 | 2013 |
| Smallpox: the triumph over the most terrible of the ministers of death N Barquet, P Domingo Annals of internal medicine 127 (8_Part_1), 635-642, 1997 | 453 | 1997 |
| Clinical utility of HIV-1 genotyping and expert advice: the Havana trial C Tural, L Ruiz, C Holtzer, J Schapiro, P Viciana, J González, P Domingo, ... Aids 16 (2), 209-218, 2002 | 440 | 2002 |
| Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection E Martínez, JA Arnaiz, D Podzamczer, D Dalmau, E Ribera, P Domingo, ... New England Journal of Medicine 349 (11), 1036-1046, 2003 | 393 | 2003 |
| Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain J Berenguer, P Ryan, J Rodriguez-Bano, I Jarrín, J Carratala, J Pachon, ... Clinical Microbiology and Infection 26 (11), 1525-1536, 2020 | 385 | 2020 |
| Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral … FA Post, GJ Moyle, HJ Stellbrink, P Domingo, D Podzamczer, M Fisher, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 49-57, 2010 | 293 | 2010 |
| Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy P Domingo, X Matias-Guiu, RM Pujol, E Francia, E Lagarda, MA Sambeat, ... Aids 13 (16), 2261-2267, 1999 | 284 | 1999 |
| Severe nucleoside-associated lactic acidosis in human immunodeficiency virus–infected patients: report of 12 cases and review of the literature V Falcó, D Rodríguez, E Ribera, E Martínez, JM Miró, P Domingo, ... Clinical infectious diseases 34 (6), 838-846, 2002 | 258 | 2002 |
| Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients JM Gallego-Escuredo, J Gómez-Ambrosi, V Catalan, P Domingo, M Giralt, ... International journal of obesity 39 (1), 121-129, 2015 | 240 | 2015 |
| Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a … L Ruiz, E Negredo, P Domingo, R Paredes, E Francia, M Balagué, S Gel, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 27 (3), 229-236, 2001 | 216 | 2001 |
| HIV and antiretroviral therapy-related fat alterations JR Koethe, C Lagathu, JE Lake, P Domingo, A Calmy, J Falutz, TT Brown, ... Nature reviews Disease primers 6 (1), 48, 2020 | 204 | 2020 |
| Infection Caused by Nocardia farcinica: Case Report and Review OH Torres, P Domingo, R Pericas, P Boiron, JA Montiel, G Vazquez European Journal of Clinical Microbiology and Infectious Diseases 19, 205-212, 2000 | 202 | 2000 |
| Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse … JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ... The Lancet Infectious Diseases 15 (7), 785-792, 2015 | 199 | 2015 |
| Clinical and microbiological features of nocardiosis 1997–2003 J Muñoz, B Mirelis, LM Aragón, N Gutiérrez, F Sánchez, M Español, ... Journal of medical microbiology 56 (4), 545-550, 2007 | 199 | 2007 |
| Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies J Reekie, C Kosa, F Engsig, AA Monforte, A Wiercinska‐Drapalo, ... Cancer 116 (22), 5306-5315, 2010 | 196 | 2010 |
| Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ... Clinical infectious diseases 62 (5), 655-663, 2016 | 192 | 2016 |
| HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy M Giralt, P Domingo, JP Guallar, MLR de la Concepción, M Alegre, ... Antiviral therapy 11 (6), 729-740, 2006 | 187 | 2006 |
| Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy J Berenguer, P Miralles, J Arrizabalaga, E Ribera, F Dronda, ... Clinical Infectious Diseases 36 (8), 1047-1052, 2003 | 184 | 2003 |
